“EpiCast Report: Growth Hormone Deficiency (GHD) - Epidemiology Forecast To 2026” states that major drivers of this growth include the launch of long-acting growth hormones, improved adherence to and compliance with the use of these growth hormones, and increased awareness of the disease within the medical profession. —
Currently, a dominant trend in the GHD market is the development of long-acting growth hormone drugs that can be administered weekly or biweekly in comparison to currently marketed daily growth hormones. In fact, all four of the late-stage pipeline drugs and two out of three drugs in early-stage development for GHD are long-acting.
In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes will increase from 109,551 cases in 2016 to 112,450 cases in 2026 at an Annual Growth Rate (AGR) of 0.26% in the 7MM. GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of GHD in all markets except Germany and Japan. In 2016, the US made up about 48% of all diagnosed prevalent cases of GHD in the 7MM. In 2016, the 5EU made up approximately 40%, and Japan made up nearly 13% of all cases of GHD in the 7MM.
Order a copy of this research report at https://www.marketinsightsreports.com/report/purchase/062215913?mode=su
This 10-year epidemiological forecast of GHD is supported by data obtained from international GHD disease monitoring databases, country-specific government sources, as well as peer reviewed studies using market-relevant disease definitions across the 7MM. This forecast provides detailed segmentations within GHD for each market by the patients age, sex, and etiological classification (congenital and idiopathic in children, and idiopathic and acquired in adults), thus creating a comprehensive view of the epidemiology of GHD in the 7MM. Epidemiologists maintained consistent forecast methodology across all seven markets, thus allowing for an accurate and meaningful comparison of included parameters among them.
Scope of the report: The Growth Hormone Deficiency (GHD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of GHD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of GHD in children (ages 18 years and younger) and adults (ages 19 years and older) segmented by age and sex. The diagnosed prevalent cases of GHD are further segmented into the classification of the disease (idiopathic and organic in children, and idiopathic and acquired in adults). Organic GHD in children is further segmented into congenital and acquired. GHD in adults is segmented by timing of disease onset: childhood onset GHD and adult onset GHD. The GHD epidemiology report is written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Complete research report of 36 pages with TOC and List of Figures is available at https://www.marketinsightsreports.com/reports/062215913/epicast-report-growth-hormone-deficiency-epidemiology-forecast-to-2026
The efficacy of the growth hormones is often reduced by non-compliance or non-adherence to the daily injection regimen. In this way, developers should continue focusing on improving delivery options and frequency of administration of growth hormones.
The GHD EpiCast report will allow you to: Develop business strategies by understanding the trends shaping and driving the global GHD market. Quantify patient populations in the global GHD market to improve product design, pricing, and launch plans. Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GHD therapeutics in each of the markets covered. Identify the percentage of GHD diagnosed prevalent cases by various clinical segmentations.
Name: Diane Conrad
Email: Send Email
Organization: Market Insights Reports
Release ID: 210418